Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism PARP1 inhibitors(Poly (ADP-Ribose) polymerase 1 inhibitors), PARP2 inhibitors(Poly (ADP-Ribose) Polymerase 2 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 2 | CN | 24 Nov 2020 | |
Ovarian Cancer | Phase 2 | CN | 24 Nov 2020 | |
BRCA mutation positive Breast Cancer | Phase 2 | CN | 01 Jul 2020 | |
BRCA mutation positive Breast Cancer | Phase 2 | CN | 01 Jul 2020 | |
Metastatic castration-resistant prostate cancer | Phase 2 | CN | 15 Jun 2020 | |
Metastatic castration-resistant prostate cancer | Phase 2 | CN | 15 Jun 2020 | |
Locally advanced breast cancer | Phase 1 | CN | 12 Aug 2020 | |
Metastatic breast cancer | Phase 1 | CN | 12 Aug 2020 | |
Neoplasm Metastasis | Phase 1 | CN | 12 Aug 2020 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 01 Oct 2016 |
NCT02940132 (ASCO2020) Manual | Phase 1 | HR-positive/HER2-low Solid Tumors BRCA Mutation (germline) | 52 | (acovzgmusf) = fqufgefald itiimyfknr (fsfzhitebp ) View more | Positive | 29 May 2020 |